Stock ROIV ROIVANT SCIENCES LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Roivant Sciences Ltd.

Equities

ROIV

BMG762791017

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
11.03 USD +1.38% Intraday chart for Roivant Sciences Ltd. +5.45% -1.78%
05/04 Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit MT
04/04 Moderna Suffers Setback in Lawsuit by Arbutus MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit
MT
Moderna Suffers Setback in Lawsuit by Arbutus
MT
Moderna shares fall after judge sides with Arbutus in patent fight
RE
Deutsche Bank Raises Roivant Sciences' Price Target to $15 From $14, Maintains Buy Rating
MT
Goldman Sachs Raises Roivant Sciences' Price Target to $18 From $16, Maintains Buy Rating
MT
HC Wainwright Raises Roivant Sciences Price Target to $18 From $17, Maintains Buy Rating
MT
Tesla, UnitedHealth Group fall; Roivant, Valero rise, Tuesday, 4/2/2024
AQ
Roivant Sciences : NIU Phase 2 Topline Results
PU
Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise
MT
Transcript : Roivant Sciences Ltd. - Special Call
Roivant Sciences Ltd. announces an Equity Buyback for $1,500 million worth of its shares.
CI
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
GL
Roivant's anti-inflammatory drug succeeds in mid-stage study
RE
Roivant and Priovant Therapeutics Announce Positive Results from the Phase 2 Study for Brepocitinib in NIU
CI
Roivant Sciences Ltd. authorizes a Buyback Plan.
CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 1000
CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 400 - Biotechnology
CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 400 Health Care
CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P Composite 1500
CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 400
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ROIV Stock
  4. News Roivant Sciences Ltd.